{"id":"NCT03547908","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-30","primaryCompletion":"2022-02-25","completion":"2024-03-07","firstPosted":"2018-06-06","resultsPosted":"2023-03-15","lastUpdate":"2025-03-19"},"enrollment":244,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1/HBV Co-Infection"],"interventions":[{"type":"DRUG","name":"B/F/TAF","otherNames":["Biktarvy®"]},{"type":"DRUG","name":"Placebo to match DTG","otherNames":[]},{"type":"DRUG","name":"Placebo to match F/TDF","otherNames":[]},{"type":"DRUG","name":"DTG","otherNames":[]},{"type":"DRUG","name":"F/TDF","otherNames":["Truvada®"]},{"type":"DRUG","name":"Placebo to match B/F/TAF","otherNames":[]}],"arms":[{"label":"Blinded Phase: B/F/TAF","type":"EXPERIMENTAL"},{"label":"Blinded Phase: DTG+F/TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open-label Extension Phase: B/F/TAF from B/F/TAF","type":"EXPERIMENTAL"},{"label":"Open-label Extension Phase: B/F/TAF from DTG+F/TDF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve and HIV-1 and hepatitis B virus (HBV) adults.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)","timeFrame":"Week 48","effectByArm":[{"arm":"Blinded Phase: B/F/TAF","deltaMin":95,"sd":null},{"arm":"Blinded Phase: DTG + F/TDF","deltaMin":91,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.2113"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":69,"countries":["United States","China","Dominican Republic","France","Greece","Hong Kong","Japan","Malaysia","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":["37494942","39250654"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-380-4458"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":121},"commonTop":["Covid-19","Upper respiratory tract infection","Nasopharyngitis","Pyrexia","Weight increased"]}}